{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:13:54Z","timestamp":1789726434056,"version":"4.0.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,3,23]],"date-time":"2024-03-23T00:00:00Z","timestamp":1711152000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,3,23]],"date-time":"2024-03-23T00:00:00Z","timestamp":1711152000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Ministry of Justice IL"},{"DOI":"10.13039\/501100003483","name":"Hebrew University of Jerusalem","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003483","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1007\/s40263-024-01077-0","type":"journal-article","created":{"date-parts":[[2024,3,23]],"date-time":"2024-03-23T12:01:41Z","timestamp":1711195301000},"page":"399-408","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["The Effect of Levetiracetam Compared with Enzyme-Inducing Antiseizure Medications on Apixaban and Rivaroxaban Peak Plasma Concentrations"],"prefix":"10.1007","volume":"38","author":[{"given":"Rachel","family":"Goldstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Rabkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noa","family":"Buchman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aviya R.","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled","family":"Sandouka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruria","family":"Raccah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamar","family":"Fisher Negev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilan","family":"Matok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2046-4171","authenticated-orcid":false,"given":"Meir","family":"Bialer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mordechai","family":"Muszkat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,23]]},"reference":[{"key":"1077_CR1","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/S1474-4422(18)30107-8","volume":"17","author":"T Tomson","year":"2018","unstructured":"Tomson T, Battino D, Bonizzoni E, Craig J, Lindhout D, Perucca E, et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurol. 2018;17:530\u20138.","journal-title":"Lancet Neurol"},{"issue":"4","key":"1077_CR2","first-page":"CD011412","volume":"14","author":"SJ Nevitt","year":"2022","unstructured":"Nevitt SJ, Sudell M, Cividini S, Marson AG, Tudur SC. Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data. Cochrane Database Syst Rev. 2022;14(4):CD011412.","journal-title":"Cochrane Database Syst Rev"},{"key":"1077_CR3","unstructured":"US Food and Drug Administration. Keppra prescribing information. 2020. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/021035s104,021505s044lbl.(pdf. Accessed 25 Jun 2023."},{"key":"1077_CR4","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","volume":"383","author":"CT Ruff","year":"2014","unstructured":"Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383:955\u201362.","journal-title":"Lancet"},{"key":"1077_CR5","doi-asserted-by":"publisher","first-page":"907197","DOI":"10.3389\/fcvm.2022.907197","volume":"9","author":"S Zeng","year":"2022","unstructured":"Zeng S, Zheng Y, Jiang J, Ma J, Zhu W, Cai X. Effectiveness and safety of DOACs vs. warfarin in patients with atrial fibrillation and frailty: a systematic review and meta-analysis. Front Cardiovasc Med. 2022;9:907197.","journal-title":"Front Cardiovasc Med."},{"key":"1077_CR6","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1007\/s40263-019-00677-5","volume":"33","author":"A Perlman","year":"2019","unstructured":"Perlman A, Wanounou M, Goldstein R, Choshen Cohen L, Singer DE, Muszkat M. Ischemic and thrombotic events associated with concomitant Xa-inhibiting direct oral anticoagulants and antiepileptic drugs: analysis of the FDA Adverse Event Reporting System (FAERS). CNS Drugs. 2019;33:1223\u20138.","journal-title":"CNS Drugs"},{"key":"1077_CR7","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s40263-021-00795-z","volume":"35","author":"A Perlman","year":"2021","unstructured":"Perlman A, Goldstein R, Choshen Cohen L, Hirsh-Raccah B, Hakimian D, Matok I, et al. Effect of enzyme-inducing antiseizure medications on the risk of sub-therapeutic concentrations of direct oral anticoagulants: a retrospective cohort study. CNS Drugs. 2021;35:305\u201316.","journal-title":"CNS Drugs"},{"key":"1077_CR8","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1002\/cpt.2369","volume":"110","author":"N Gronich","year":"2021","unstructured":"Gronich N, Stein N, Muszkat M. Association between use of pharmacokinetic-interacting drugs and effectiveness and safety of direct acting oral anticoagulants: nested case-control study. Clin Pharmacol Ther. 2021;110:1526\u201336.","journal-title":"Clin Pharmacol Ther"},{"key":"1077_CR9","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1007\/s40263-022-00971-9","volume":"36","author":"BY Ip","year":"2022","unstructured":"Ip BY, Ko H, Wong GL, Yip TC, Lau LH, Lau AY, et al. Thromboembolic risks with concurrent direct oral anticoagulants and antiseizure medications: a population-based analysis. CNS Drugs. 2022;36:1313\u201324.","journal-title":"CNS Drugs"},{"key":"1077_CR10","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1111\/epi.17822","volume":"65","author":"H Cohen","year":"2024","unstructured":"Cohen H, Mahajna G, Ben-Shushan T, Matok I, Eyal S. The extent of cytochrome P450 3A induction by antiseizure medications: a systematic review and network meta-analysis. Epilepsia. 2024;65:445\u201355.","journal-title":"Epilepsia"},{"key":"1077_CR11","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s40263-023-00990-0","volume":"37","author":"R Goldstein","year":"2023","unstructured":"Goldstein R, Jacobs AR, Zighan L, Gronich N, Bialer M, Muszkat M. Interactions between direct oral anticoagulants (DOACs) and antiseizure medications: potential implications on DOAC treatment. CNS Drugs. 2023;37:203\u201314.","journal-title":"CNS Drugs"},{"key":"1077_CR12","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1093\/europace\/euab065","volume":"23","author":"J Steffel","year":"2021","unstructured":"Steffel J, Collins R, Antz M, Cornu P, Desteghe L, Haeusler KG, et al. 2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. EP Europace. 2021;23:1612\u201376.","journal-title":"EP Europace."},{"key":"1077_CR13","doi-asserted-by":"publisher","first-page":"82","DOI":"10.2174\/156720208784310196","volume":"5","author":"L Lombardo","year":"2008","unstructured":"Lombardo L, Pellitteri R, Balazy M, Cardile V. Induction of nuclear receptors and drug resistance in the brain microvascular endothelial cells treated with antiepileptic drugs. Curr Neurovasc Res. 2008;5:82\u201392.","journal-title":"Curr Neurovasc Res"},{"key":"1077_CR14","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.eplepsyres.2010.12.013","volume":"94","author":"L Moerman","year":"2011","unstructured":"Moerman L, wyffels L, Slaets D, Raedt R, Boon P, De Vos F. Antiepileptic drugs modulate P-glycoproteins in the brain: a mice study with 11C-desmethylloperamide. Epilepsy Res. 2011;94:18\u201325.","journal-title":"Epilepsy Res"},{"key":"1077_CR15","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/S0920-1211(01)00253-4","volume":"46","author":"RH Levy","year":"2001","unstructured":"Levy RH, Ragueneau-Majlessi I, Baltes E. Repeated administration of the novel antiepileptic agent levetiracetam does not alter digoxin pharmacokinetics and pharmacodynamics in healthy volunteers. Epilepsy Res. 2001;46:93\u20139.","journal-title":"Epilepsy Res"},{"key":"1077_CR16","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1007\/s40263-023-01052-1","volume":"37","author":"M Abou Kaoud","year":"2023","unstructured":"Abou Kaoud M, Nissan R, Segev A, Sabbag A, Orion D, Maor E. Levetiracetam interaction with direct oral anticoagulants: a pharmacovigilance study. CNS Drugs. 2023;37:1111\u201321.","journal-title":"CNS Drugs"},{"key":"1077_CR17","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13584-019-0285-9","volume":"8","author":"A Perlman","year":"2019","unstructured":"Perlman A, Horwitz E, Hirsh-Raccah B, Aldouby-Bier G, Fisher Negev T, Hochberg-Klein S, et al. Clinical pharmacist led hospital-wide direct oral anticoagulant stewardship program. Isr J Health Policy Res. 2019;8:19.","journal-title":"Isr J Health Policy Res"},{"key":"1077_CR18","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.5858\/arpa.2013-0750-OA","volume":"138","author":"RC Gosselin","year":"2014","unstructured":"Gosselin RC, Funk (Adcock) DM, Taylor JM, Francart SJ, Hawes EM, Friedman KD, et al. Comparison of anti-Xa and dilute Russell viper venom time assays in quantifying drug levels in patients on therapeutic doses of rivaroxaban. Arch Pathol Lab Med. 2014;138:1680\u20134.","journal-title":"Arch Pathol Lab Med"},{"key":"1077_CR19","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s11239-011-0591-8","volume":"32","author":"RC Becker","year":"2011","unstructured":"Becker RC, Yang H, Barrett Y, Mohan P, Wang J, Wallentin L, et al. Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban: an oral, direct and selective factor Xa inhibitor. J Thromb Thrombolysis. 2011;32:183\u20137.","journal-title":"J Thromb Thrombolysis"},{"key":"1077_CR20","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1001\/jamacardio.2017.0364","volume":"2","author":"JW Eikelboom","year":"2017","unstructured":"Eikelboom JW, Quinlan DJ, Hirsh J, Connolly SJ, Weitz JI. Laboratory monitoring of non-vitamin K antagonist oral anticoagulant use in patients with atrial fibrillation: a review. JAMA Cardiol. 2017;2:566.","journal-title":"JAMA Cardiol."},{"key":"1077_CR21","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1055\/s-0038-1627480","volume":"118","author":"R Gosselin","year":"2018","unstructured":"Gosselin R, Adcock D, Bates S, Douxfils J, Favaloro E, Gouin-Thibault I, et al. International Council for Standardization in Haematology (ICSH) recommendations for laboratory measurement of direct oral anticoagulants. Thromb Haemost. 2018;118:437\u201350.","journal-title":"Thromb Haemost"},{"key":"1077_CR22","unstructured":"DrugBank. Cytochrome P-450 CYP3A4 inducers. Available from: https:\/\/www.drugbank.ca\/categories\/DBCAT003896. Accessed 9 Jun 2020."},{"key":"1077_CR23","unstructured":"US Food and Drug Administration. For healthcare professionals: FDA\u2019s examples of drugs that interact with CYP enzymes and transporter systems. 2023. Available from: https:\/\/www.fda.gov\/drugs\/drug-interactions-labeling\/healthcare-professionals-fdas-examples-drugs-interact-cyp-enzymes-and-transporter-systems. Accessed 5 Mar 2024."},{"key":"1077_CR24","doi-asserted-by":"publisher","first-page":"e604","DOI":"10.1161\/CIR.0000000000000477","volume":"135","author":"AN Raval","year":"2017","unstructured":"Raval AN, Cigarroa JE, Chung MK, Diaz-Sandoval LJ, Diercks D, Piccini JP, et al. Management of patients on non-vitamin K antagonist oral anticoagulants in the acute care and periprocedural setting: a scientific statement from the American Heart Association. Circulation. 2017;135:e604\u201333.","journal-title":"Circulation"},{"key":"1077_CR25","volume":"15","author":"M Mangiardi","year":"2023","unstructured":"Mangiardi M, Iaccarino G, Alessiani M, Bonura A, Anticoli S. Treating post-stroke epilepsy in a patient with multiple comorbidities. Cureus. 2023;15: e38483.","journal-title":"Cureus."},{"key":"1077_CR26","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.seizure.2018.08.001","volume":"61","author":"F Brigo","year":"2018","unstructured":"Brigo F, Lattanzi S, Zelano J, Bragazzi NL, Belcastro V, Nardone R, et al. Randomized controlled trials of antiepileptic drugs for the treatment of post-stroke seizures: a systematic review with network meta-analysis. Seizure. 2018;61:57\u201362.","journal-title":"Seizure."},{"key":"1077_CR27","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1111\/epi.12926","volume":"56","author":"KJ Werhahn","year":"2015","unstructured":"Werhahn KJ, Trinka E, Dobesberger J, Unterberger I, Baum P, Deckert-Schmitz M, et al. A randomized, double-blind comparison of antiepileptic drug treatment in the elderly with new-onset focal epilepsy. Epilepsia. 2015;56:450\u20139.","journal-title":"Epilepsia"},{"key":"1077_CR28","doi-asserted-by":"publisher","first-page":"71","DOI":"10.7326\/L19-0712","volume":"173","author":"F Paciullo","year":"2020","unstructured":"Paciullo F, Costa C, Gresele P. Rivaroxaban plasma levels and levetiracetam: a case report. Ann Intern Med. 2020;173:71\u20132.","journal-title":"Ann Intern Med"},{"key":"1077_CR29","doi-asserted-by":"publisher","first-page":"9257","DOI":"10.1038\/s41598-023-33876-8","volume":"13","author":"A Mavri","year":"2023","unstructured":"Mavri A, Ilc S. The efficacy of direct oral anticoagulants in patients on concomitant treatment with levetiracetam. Sci Rep. 2023;13:9257.","journal-title":"Sci Rep"},{"key":"1077_CR30","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s10072-023-06992-6","volume":"45","author":"F Ranzato","year":"2024","unstructured":"Ranzato F, Roberti R, Deluca C, Carta M, Peretti A, Polo D, et al. Pilot study on the probability of drug-drug interactions among direct oral anticoagulants (DOACs) and antiseizure medications (ASMs): a clinical perspective. Neurol Sci. 2024;45:277\u201388.","journal-title":"Neurol Sci"},{"key":"1077_CR31","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1093\/ehjcvp\/pvad070","volume":"9","author":"M Grymonprez","year":"2023","unstructured":"Grymonprez M, Carnoy L, Capiau A, Boussery K, Mehuys E, De Backer TL, et al. Impact of P-glycoprotein and CYP3A4-interacting drugs on clinical outcomes in patients with atrial fibrillation using non-vitamin K antagonist oral anticoagulants: a nationwide cohort study. Eu Heart J Cardiovasc Pharmacother. 2023;9:722\u201330.","journal-title":"Eu Heart J Cardiovasc Pharmacother."},{"key":"1077_CR32","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s40261-020-00982-8","volume":"41","author":"M Giustozzi","year":"2021","unstructured":"Giustozzi M, Mazzetti M, Paciaroni M, Agnelli G, Becattini C, Vedovati MC. Concomitant use of direct oral anticoagulants and antiepileptic drugs: a prospective cohort study in patients with atrial fibrillation. Clin Drug Investig. 2021;41:43\u201351.","journal-title":"Clin Drug Investig"},{"key":"1077_CR33","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1093\/ehjcvp\/pvz035","volume":"6","author":"C-L Wang","year":"2020","unstructured":"Wang C-L, Wu VC-C, Chang K-H, Tu H-T, Kuo C-F, Huang Y-T, et al. Assessing major bleeding risk in atrial fibrillation patients concurrently taking non-vitamin K antagonist oral anticoagulants and antiepileptic drugs. Eur Heart J Cardiovasc Pharmacother. 2020;6:147\u201354.","journal-title":"Eur Heart J Cardiovasc Pharmacother."},{"key":"1077_CR34","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/s12883-021-02237-1","volume":"21","author":"M Giner-Soriano","year":"2021","unstructured":"Giner-Soriano M, Marsal JR, Gomez-Lumbreras A, Morros R. Risk of ischaemic stroke associated with antiepileptic drugs: a population-based case-control study in Catalonia. BMC Neurol. 2021;21:208.","journal-title":"BMC Neurol"},{"key":"1077_CR35","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.seizure.2014.02.007","volume":"23","author":"C-S Chang","year":"2014","unstructured":"Chang C-S, Liao C-H, Lin C-C, Lane H-Y, Sung F-C, Kao C-H. Patients with epilepsy are at an increased risk of subsequent stroke: a population-based cohort study. Seizure. 2014;23:377\u201381.","journal-title":"Seizure."},{"key":"1077_CR36","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-008365","volume":"5","author":"C Renoux","year":"2015","unstructured":"Renoux C, Dell\u2019Aniello S, Saarela O, Filion KB, Boivin J-F. Antiepileptic drugs and the risk of ischaemic stroke and myocardial infarction: a population-based cohort study. BMJ Open. 2015;5: e008365.","journal-title":"BMJ Open"},{"key":"1077_CR37","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.seizure.2020.01.009","volume":"76","author":"P Redfors","year":"2020","unstructured":"Redfors P, Holmegaard L, Pedersen A, Jern C, Malmgren K. Long-term follow-up of post-stroke epilepsy after ischemic stroke: room for improved epilepsy treatment. Seizure. 2020;76:50\u20135.","journal-title":"Seizure."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-024-01077-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-024-01077-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-024-01077-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T12:18:01Z","timestamp":1713442681000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-024-01077-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,23]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["1077"],"URL":"https:\/\/doi.org\/10.1007\/s40263-024-01077-0","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,23]]},"assertion":[{"value":"25 February 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open access funding provided by Hebrew University of Jerusalem. This work was funded by a research grant from the Estates Committee, Israel Ministry of Justice (proposal submitted to the Chief Scientist, Ministry of Health) to Mordechai Muszkat 2021\u201324.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Meir Bialer received speaker\u2019s or consultancy fees from Clexio Bioscines, Guidepoint, Meditec (Sam-On,) Pharma Two B, Selene Therapeurics, Shackelford Pharamad, USWorldMeds, and Xenon Pharma. Mordechai Muszkat recieved honorarai from Roche and a research grant from the Pfizer Independent Galobal Medical Grant. Rachel Goldstein, Natalie Rabkin, Noa Buchman, Aviya R. Jacobs, Khaled Sandouka, Bruria Raccah, Tamar Fisher Negev, and Ilan Matok have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"RG and MM had the idea for the article. The literature search and data analysis were performed by RG, NR, NB, ARJ, KS, BR, TF, IM and MM. RG, NR, NB, ARJ, KS, BR, and TF produced an initial draft of the manuscript under guidance and supervision from IM, MB, and MM. RG, NR, MB, and MM contributed to a critical evaluation of the data and to the revision and finalization of the manuscript. All authors have read and approved the final version of the manuscript and agree to be accountable for the work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}